Participant characteristics | N | Prevalence (%) (95% CI) | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) |
---|---|---|---|---|
Overall (symptomatic and asymptomatic participants) | ||||
 Kabuta | 138a | 23.2 (16.4 – 31.1) | 62.5 (43.7 – 78.9) | 100.0 (96.6 –100.0) |
 Kafutuma | 144 | 18.8 (12.7 – 26.1) | 77.8 (57.7 – 91.4) | 99.1 (95.3 – 100.0) |
 Kashikishi | 450a | 26.4 (22.4 – 30.8) | 59.7 (50.3 – 68.6) | 99.7 (98.3 – 100.0) |
 Nchelenge | 280 | 19.6 (15.2 – 24.8) | 72.7 (59.0 – 83.9) | 99.6 (97.5 – 100.0) |
 Pooled estimate | 1,012a | 22.3 (18.4 – 26.2) | 66.4 (57.7 – 74.1) | 99.6 (98.8 – 99.9) |
Positive likelihood ratio = 171.2 (54.2 – 541.1) | ||||
Negative likelihood ratio = 0.34 (0.26 – 0.43) | ||||
Diagnostic odds ratio = 508 (156 – 1655) | ||||
Asymptomatic participants | ||||
 Kabuta | 96a | 18.8 (11.5 – 28.0) | 55.6 (30.8 – 78.5) | 100.0 (95.4 – 100.0) |
 Kafutuma | 111 | 17.1 (10.6 – 25.4) | 73.7 (48.8 – 90.9) | 98.9 (94.1 – 100.0) |
 Kashikishi | 371a | 24.5 (20.2 – 29.2) | 52.7 (42.0 – 63.3) | 99.6 (98.0 – 100.0) |
 Nchelenge | 236 | 18.6 (13.9 – 24.2) | 68.2 (52.4 – 81.4) | 100.0 (98.1 – 100.0) |
 Pooled estimate | 814a | 20.4 (16.7 – 24.0) | 60.4 (50.3 – 69.7) | 99.7 (98.7—99.9) |
Positive likelihood ratio = 195.2 (46.8 – 813.8) | ||||
Negative likelihood ratio = 0.40 (0.31 – 0.51) | ||||
Diagnostic odds ratio = 491 (112 – 2159) | ||||
Symptomatic participants | ||||
 Kabuta | 41a | 31.7 (18.1 – 48.1) | 69.2 (38.6 – 90.9) | 100.0 (87.7 – 100.0) |
 Kafutuma | 33 | 24.2 (11.1 – 42.3) | 100.0 (63.1 – 100.0) | 100.0 (86.3 – 100.0) |
 Kashikishi | 78a | 35.9 (25.3 – 47.6) | 82.1 (63.1 – 93.9) | 100.0 (92.9 – 100.0) |
 Nchelenge | 44 | 25.0 (13.2 – 40.3) | 90.9 (58.7 – 99.8) | 97.0 (84.2 – 99.9) |
 Symptomatic | 196a | 30.1 (23.7 – 36.5) | 83.6 (70.1 – 91.7) | 99.3 (90.7—100.0) |
Positive likelihood ratio = 124.0 (8.2 – 1881.8) | ||||
Negative likelihood ratio = 0.17 (0.09 – 0.32) | ||||
Diagnostic odds ratio = 749 (39 – 14,320) |